Data Sheet (Cat.No.T11667)



Ipragliflozin (L-Proline)

Chemical Properties				
CAS No. :	951382-34-6			
Formula:	C26H30FN07S			
Molecular Weight:	519.58 [©]			
Appearance:	no data available			
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year			

Biological Description

Description	Ipragliflozin is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; lite and NO potency for SGLT1/3/4/5/6.		
Targets(IC50)	Others		
In vitro	Ipragliflozin selectively and potently inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases.		
In vivo	Following oral administration, ipragliflozin demonstrates favorable pharmacokinetic properties and dose-dependently enhances urinary glucose excretion, with effects lasting over 12 hours in normal mice. This increase in urinary glucose excretion is significant at doses of 0.3 mg/kg or higher. Additionally, a single dose of ipragliflozin effectively increases urinary glucose excretion, lowers blood glucose and plasma insulin levels, and ameliorates glucose intolerance.		

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9246 mL	9.6232 mL	19.2463 mL
5 mM	0.3849 mL	1.9246 mL	3.8493 mL
10 mM	0.1925 mL	0.9623 mL	1.9246 mL
50 mM	0.0385 mL	0.1925 mL	0.3849 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Imamura M, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Inhibitor • Natural Compounds • Compound Libraries • Recombinant ProteinsThis product is for Research Use Only• Not for Human or Veterinary or Therapeutic UseTel:781-999-4286E_mail:info@targetmol.comAddress:36 Washington Street,Wellesley Hills,MA 02481